1 Title: Use of illness severity scores to predict mortality in interstitial lung disease 2 patients hospitalised with acute respiratory deterioration Rachel L Williams^{1,2†}, Catherine Hyams^{1,3,4,5†}, Joe Robertshaw^{1,3}, Maria Garcia Gonzalez^{4,5}, 3 Zsuzsa Szasz-Benczur⁴, Paul White⁶, Nick A Maskell¹, Adam Finn⁴ and Shaney L Barratt^{1,3} 4 on behalf on the AvonCAP Research Group 5 6 ¹ Academic Respiratory Unit, University of Bristol, North Bristol NHS Trust, Southmead, 7 8 Bristol, BS10 5NB ² Research and Innovation, North Bristol NHS Trust, Southmead, Bristol BS10 5NB 9 ³ Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Southmead, Bristol 10 11 **BS10 5NB** 12 ⁴ Bristol Vaccine Centre, Schools of Population Health Sciences and Cellular and Molecular 13 Medicine, University of Bristol, Bristol, BS2 8AE ⁵ Vaccine and Testing Team, UHBW NHS Trust, Bristol 14 ⁶ University of the West of England, Bristol, BS16 1QY 15 [†] These authors contributed equally to this work 16 17 **Correspondence to:** Dr Shaney Barratt, 18 Bristol Interstitial Lung Disease Service, 19 20 North Bristol NHS Trust, Southmead Hospital, 21 Bristol BS10 5NB, UK 22 shaney.barratt@nbt.nhs.uk 23 24 The AvonCAP study is an investigator-led University of Bristol **Funding:** 25 sponsored study which was designed and implemented collaboratively 26 with Pfizer, Inc. which also funded the study. For the current 27 manuscript, Pfizer staff did not play any part in data collection, 28 analysis plan, data analysis or manuscript preparation

29 **ABSTRACT** 30 Introduction 31 Hospitalisations relating to acute respiratory deteriorations (ARD) in Interstitial Lung 32 Disease (ILD) have poor outcomes. Factors predicting adverse outcomes are not fully 33 understood and data addressing the use of illness severity scores in prognostication are 34 limited. 35 36 **Objective** 37 To validate the use of CURB-65 and NEWS-2 severity scores to predict mortality following 38 ARD-ILD hospitalisation. 39 40 Methods 41 A dual-centre prospective observational cohort study of all adults (≥18y) hospitalised with 42 ARD-ILD in Bristol, UK (n=179). Gender-Age-Physiology (GAP), CURB-65 and NEWS-2 43 scores were calculated for each eligible admission. 44 45 Receiver operating characteristics (ROC) curve analysis was used to quantify the strength of 46 discrimination for NEWS-2 and CURB-65 scores. Univariable and multivariable logistic 47 regression analyses were performed to explore the relationship between baseline severity 48 scores and mortality. 49 50 **Results** 51 GAP showed some merit at predicting 30-day mortality (AUC=0.64, P=0.015); whereas 52 CURB-65 showed modest predictive value for in-hospital (AUC=0.72, P<0.001) and 90-day 53 mortality (AUC=0.67, P<0.001). NEWS-2 showed higher predictive value for in-hospital

(AUC=0.80, *P*<0.001) and 90-day mortality (AUC=0.75, *P*<0.001), with an optimal derived cut-off ≥6.5 found to be sensitive and specific for predicting in-hospital (83% and 63%) and 90-day (73% and 72%) mortality. In exploratory analyses, GAP score addition improved the predictive ability of NEWS-2 against 30-day mortality and CURB-65 across all time-periods.

Conclusion

NEWS-2 has good discriminatory value for predicting in-hospital mortality and moderate discriminatory value for predicting 90-day mortality. The optimal NEWS-2 cut-off value determined was the same as in a previous retrospective cohort, confirming the NEWS-2 score shows promise in predicting mortality following ARD-ILD hospitalisation.

KEY MESSAGES

64

65

66

67

68

69

70

73

75

What is the key question?

- Can NEWS-2 and CURB-65 be used to predict inpatient mortality in a cohort of patients with acute respiratory deterioration on a background of known interstitial
- What is the bottom line?

lung disease?

- The NEWS-2 score shows high sensitivity and specificity in predicting both 90-day and in-hospital mortality in patients hospitalised with ARD-ILD
- a low specificity, and did not add value to the predictive ability of the NEWS-2 score.

Whilst the CURB-65 score showed high sensitivity for predicting mortality, there was

76 Why read on?

- 77 This analysis included 179 patients from two study sites and provides, for the first
- time, prospective evidence for utilising NEWS-2 and CURB-65 as tools to predict in-
- 79 hospital and post hospitalisation morbidity.

INTRODUCTION

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

Idiopathic pulmonary fibrosis (IPF) is considered the archetypal chronic progressive fibrotic Interstitial Lung Disease (ILD), which can have an unpredictable clinical course punctuated by sudden, severe acute respiratory deteriorations (ARD). ARD related hospitalisations in IPF patients are associated with poor patient outcomes, posing a significant burden on healthcare services. 1-4 ARD-IPF are categorised into parenchymal and extra-parenchymal causes within a conceptual framework. Acute exacerbation (AE), defined within this framework describes rapid respiratory deterioration associated with new widespread parenchymal ground glass opacification (with or without consolidation) on the background of established fibrosis and is not fully explained by fluid overload or cardiac failure. Mortality associated with AE-IPF is high; 1,5 although, factors predicting adverse outcomes are not fully understood. Whilst originally described in IPF, both ARD and AE are increasingly considered to be features of other fibrosing ILDs; although, their epidemiology and triggers in non-IPF ILDs are less well understood, with no randomised controlled trials examining optimal management.⁵ The emergence of SARS-CoV-2 and resultant pandemic have severely impacted healthcare provision, with ILD patients at increased risk of severe COVID-19 disease, possibly attributable to immunosuppressive treatment in addition to their chronic lung changes.⁶⁻⁸ Ensuring appropriate healthcare resource allocation and usage, especially with the significant ILD disease burden, may be aided by validated illness scores as predictors of mortality. The CURB-65 score was validated against 30-day mortality in pneumonia, 9 and subsequently validated against other conditions including sepsis. The National Early Warning Score-2 (NEWS-2) is used throughout UK hospitals to rapidly identify patients at risk of

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

deterioration, 10 and also to predict in-hospital mortality. There are few data on the use of illness severity scores to predict short to medium term outcomes following admission. 11-13 Our previous single-centre, retrospective, observational cohort study of 172 IPF patients admitted with ARD, supported the use of CURB-65 and NEWS-2 illness severity scores to predict in-hospital and 90-day mortality. ARD-IPF mortality was high irrespective of cause, in-line with mortality estimates from other published cohorts;³ however, data also suggests AE-IPF mortality is higher compared to other parenchymal causes of ARD.¹⁴ The AvonCAP prospective observational study of acute lower respiratory tract disease (aLRTD) provided the opportunity to evaluate CURB-65 and NEWS-2 usage as predictors of mortality in a broad cohort of patients with ARD-ILD hospitalisations following the emergence of SARS-CoV-2. We describe the characteristics of a prospective cohort of patients hospitalised with ARD-ILD, comparing those patients with IPF and non-IPF ILDs and investigating factors associated with worse outcome. **METHODS Study Design** A prospective, dual-centre observational cohort study undertaken at North Bristol and University Hospitals Bristol and Weston NHS Foundation Trusts, encompassing all secondary care institutions in Bristol, UK, as part of the AvonCAP study. The study was approved by the Health Research Authority East of England Ethics Committee, including use of Section 251 of the 2006 NHS Act approved by the Confidentiality Advisory Group (REC:20/EE/0157, ISRCTN:17354061).

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

Study Subjects Patients hospitalised with worsening respiratory signs/symptoms between 1st August 2020 and 9th November 2021 were screened. Full inclusion and exclusion criteria are available on IRSCTN. 15 Only individuals with a multidisciplinary team (MDT)-confirmed diagnosis of ILD (either pre-existing or arising from the hospitalisation), including but not limited to IPF, were included in this analysis. Collection of clinical data was undertaken on all eligible participants using a standardised REDCap proforma¹⁶. Lung Function Tests (LFTs) and 6-min walk test (6MWT) were included if conducted within 6-months of hospitalisation and were not performed specifically for this study. Gender-Age-Physiology (GAP), CURB-65 and NEWS-2 scores were calculated for each hospital admission. 9,17-19 **Case Definitions** The aetiology of ARD-ILD was categorised according to Collard's conceptual framework: (1) Extra-parenchymal causes: pleural effusion, pneumothorax or pulmonary embolism, (2) AE-ILD: diagnosed in accordance with broadened Collard et al. revised criteria 20 to include all fibrosing ILDs: previous/concurrent ILD, worsening dyspnoea <1 month duration, new bilateral ground-glass opacification (with/without consolidation) on CT imaging, superimposed on background of established fibrosis and not fully explained by cardiac failure/ fluid overload. AE-ILD was further sub-categorised into triggered (clear precipitant) or idiopathic. (3) Not AE-ILD: other parenchymal ARD-ILD causes not attributed to an AE, including: non-pneumonic lower respiratory tract infection (NP-LRTI)/presumed NP-LRTI (defined in the context of a CT not clearly identifying a radiological cause for the deterioration or

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

unchanged CXR (presumed) but CRP>6mg/ml); pneumonia; cardiac failure/fluid overload; disease progression; and, those with non-specific trigger (no radiological cause demonstrated on CT imaging with CRP<6mg/ml; for example: anxiety, symptom control and/or palliation). (4) Not fully classified ARD-ILD: hospitalisation without CT imaging on admission but unaltered chest radiograph and CRP <6mg/ml and no clear trigger. **Outcome Measures** The primary outcome was to validate previously determined baseline CURB-65 score ≥3.5 and NEWS-2 score ≥6.5 as predictors of in-hospital mortality⁴ in a broader group of patients with ILD. Secondary outcomes were to determine the utility of the GAP score to predict in-hospital, 30and 90-day mortality rates in patients with ARD-ILD, in addition to determining the overall in-hospital, 30- and 90-day mortality rates for patients with ARD-ILD, hospital length of stay (LOS), thereby highlighting any differences in mortality between IPF and non-IPF ARD cohorts. **Statistical Analysis** Categorical data were presented as numbers and proportions (n, %), continuous nonparametric data as medians and interquartile range (IQR). Either log rank test, Fisher's exact test or chi-square test was used where appropriate to analyse differences between groups. For the primary analysis, univariable and multivariable logistic regression analyses were performed to explore the relationship between baseline severity scores and mortality. The factors used in the multivariable model were decided a priori and were smoking status, GAP

score, CURB-65 and NEWS-2 score. Receiver operating characteristic (ROC) curve analysis was used to quantify the strength of discrimination. Previous data suggested cut-offs of CURB-65>3.5 and NEWS-2>6.5, provided Area Under the Receiver Operating Curve (AUROC) estimates of 0.85 and 0.89 respectively, in the prediction of in-hospital mortality in hospitalised ARD-IPF.⁴ Assuming an inpatient mortality rate approximating 20%.⁴ a consecutive sample size of 175 patients would be sufficient to validate an AUROC≥0.8 with a lower 95% confidence interval (CI) of the AUROC exceeding a lower acceptability threshold of 0.7.²¹ Power calculations were performed using the proprietary Power Analysis & Sample Size (PASS) software.

The impact of prognostic factors on survival was computed using a Kaplan-Meier analysis and multivariate Cox proportional hazards model. For all tests, a P<0.05 was considered statistically significant. Data were analysed using IBM SPSS v28.0.

RESULTS

Patient Demographics

Of the total 132,097 patients ≥18 years hospitalised in the study period: 179 patients had confirmed ARD with a multidisciplinary diagnosis of ILD (Figure 1A). The median age of patients was 75 years (IQR 72-84), 64% were male and 57% were ex-smokers (Table 1). IPF was the underlying diagnosis of 40% of the cohort, but a broad range of other ILD diagnoses existed, including: unclassifiable ILD (13%), hypersensitivity pneumonitis (HP) (12%), and connective tissue disease associated-ILD (10%) (Table 1). *De novo* presentations with ILD were infrequent (3% ILD admissions). Patients had moderately restrictive disease (median FVC% predicted 75 (IQR 63-91), TLCO 44% (IQR 33-58) and a median GAP score of 4

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

(IQR 3-5), corresponding to GAP stage II. Approximately one third of patients had at least 2 or more (31%, n=56) concurrent medical co-morbidities. Overall, vaccination rates were high in the cohort: 75% of patients having received pneumococcal and seasonal influenza vaccination by the time of admission, and 83% of eligible patients (Supplementary Data 1) having received at least one dose of a COVID-19 vaccination prior to admission. IPF patients were statistically older than those with non-IPF ILD diagnoses (IPF 81 years vs non-IPF 77 years, P=0.0068), more likely to be male (IPF 77% vs non-IPF 55%, Fisher's exact test, P = 0.004), with lower TLCO % predicted (IPF 38% vs non-IPF 54%, P = 0.0002) and higher GAP scores (IPF 5 vs non-IPF 4, P<0.0001) on hospitalisation. IPF and non-IPF ILD patients had comparable baseline spirometry values (Table 1). **Underlying Actiology** Most (79%) ARD-ILD admissions were due to parenchymal causes other than AE-ILD (Figure 1B). Pneumonia was the most common parenchymal cause (57%, 77/141); the vast majority were community-acquired (83% of pneumonias, n=63), with COVID-19 pneumonitis in eleven patients (14%). Other parenchymal causes included cardiac failure (n=21, 15%), NP-LRTI (n=24, 17%, including 3 patients with symptomatic COVID) and disease progression in n=5 (4%). An extra-parenchymal pathology was considered the cause of ARD in 12 patients (7%); 7 with pulmonary embolism, 3 with pleural effusion/empyema, with pneumomediastinum and anaphylaxis in the remaining patients. Non-specific triggers of ARD were identified in approximately 10% of patients and these admissions were related to requirements for palliation and symptom control, including anxiety and breathlessness. AE-ILD was rare in this cohort (n=3, 2%) and seen in patients

with fibrotic hypersensitivity pneumonitis and IPF. Due to low incidence of AE-ILD we were not able to perform analyses to determine differences between patients admitted with AE-ILD

and other parenchymal causes.

| Characteristic | ARD-ILD | IPF | Non IPF | P-value |
|--------------------------------|----------------------|---------------------|---------------------|---------|
| | n = 179 | n = 70 | n = 109 | |
| Male, n (%) | 114 (64) | 54 (77) | 60 (55) | 0.0040 |
| Age (years), median (IQR) | 79 (72-84) | 81 (75-86) | 77 (70-83) | 0.0068 |
| Smoking Status, n (%) | , | , | , , | 0.2537 |
| Current | 9 (5) | 4 (6) | 5 (5) | |
| Ex-smoker | 102 (57) | 48 (69) | 54 (50) | |
| Never | 53 (30) | 14 (20) | 39 (36) | |
| Unknown | 15 (8) | 4 (6) | 11 (10) | |
| Ethnicity, n (%) | | | | 0.7566 |
| Caucasian | 148 (83) | 58 (83) | 90 (83) | |
| Other | 11 (6) | 6 (9) | 5 (5) | |
| Unknown | 20 (11) | 6 (9) | 14 (13) | |
| CCI, median (IQR) | 5 (4-6) | 5 (4-6) | 5 (3-6) | 0.8765 |
| Aetiology ILD, n (%) | | | | N/A |
| IPF | 70 (39) | 70 (39) | - | |
| Unclassifiable | 23 (13) | - | 23 (13) | |
| Hypersensitivity pneumonitis | 22 (12) | - | 22 (12) | |
| CTD-ILD | 17 (10) | - | 17 (10) | |
| Smoking related ILD | 14 (8) | - | 14 (8) | |
| CPFE | 9 (5) | - | 9 (5) | |
| NSIP | 8 (5) | - | 8 (5) | |
| Sarcoid | 6 (3) | - | 6 (3) | |
| Asbestosis | 4 (2) | - | 4 (2) | |
| Other | 6 (3) | - | 6 (3) | |
| Baseline PFTs, median (IQR) | | | | |
| Lung function | | | | |
| FEV1 % predicted | 78 (66-93), n=168 | 81 (69-93), n=68 | 75 (63-93), n=100 | 0.562 |
| FVC % predicted | 75 (63-91), n=168 | 75 (64-89), n=68 | 77 (63-96, n=100 | 0.5324 |
| TLCO % predicted | 44 (33-58), n=137 | 40 (30-46), n=58 | 54 (37-61), n=79 | 0.0002 |
| 6MWT distance (m) | 240 (155-311), n=133 | 240 (130-290), n=60 | 245 (168-354), n=73 | 0.7552 |
| 6MWT minimum sats (%) | 87 (84-90) n=133 | 87 (84-89), n=60 | 87 (84-90), n=73 | 0.8129 |
| Total GAP score | 4 (3-5), n=150 | 5 (4-6), n=61 | 4 (3-5), n=89 | <0.000 |
| Admission Severity Scores | | | | |
| CURB-65, median (IQR) | 2 (1-4) | 2 (1-4) | 1 (1-3) | 0.0096 |
| NEWS-2, median (IQR) | 6 (3-8) | 6 (3-8) | 5 (2-8) | 0.4246 |
| Respiratory Support, n (%) | | | | |
| None | 20 (11) | 10 (14) | 10 (9) | 0.1382 |
| Oxygen | 159 (89) | 60 (86) | 99 (91) | 0.1482 |
| HFNO | 20 (11) | 8 (11) | 12 (11) | 1.0000 |
| NIV | 8 (4) | 5 (7) | 3 (3) | 0.2123 |
| IMV | 1(1) | 0 (0) | 1(1) | 0.4033 |
| Treatment, n (%) | 1 (1) | 0 (0) | 1 (1) | 0.1055 |
| Received antibiotics (>2 days) | 139 (78) | 52 (71) | 86 (79) | 0.4391 |
| • • | * * | 53 (74) | | |
| Received corticosteroids | 49 (27) | 18 (26) | 31 (28) | 0.7702 |
| Length of stay, median (IQR) | - | _ , | | |
| Hospitalisation days | 6 (3-11) | 7 (3-11) | 6 (3-11) | 0.545 |
| Mortality, n (%) | | | | |
| In-hospital mortality | 34 (19) | 17 (24) | 17 (16) | 0.1848 |
| 30-day mortality | | | 21 (19) | 0.090 |
| 90-day mortality | 69 (39) | 33 (47) | 36 (33) | 0.0614 |
| Survival days, median (IQR) | 59 (10-144), n=101 | 23 (10-23), n=41 | 79 (13-144), n=60 | 0.0417 |

234

235236

237

238239

240

241

242

243

244245246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

P-values represent the result of a Log-rank Test or Fisher's exact test between IPF and non-IPF groups ☐ Other includes lymphocytic interstitial pneumonia, Langerhan's cell histiocytosis, pleuroparenchymal fibroelastosis, Rosai-Dorfman, organising pneumonia. 6MWT, 6-minute walk test; ARD, acute respiratory deterioration; CCI, Charlson comorbidity index; CPFE, combined pulmonary fibrosis & emphysema; CTD-ILD, connective tissue disease ILD; GAP, gender, age and physiology score; HFNO, high flow nasal oxygen; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; IMV, invasive mechanical ventilation; IQR, interquartile range; NIV, non-invasive ventilation NSIP, non-specific interstitial pneumonia; PFTs, pulmonary function tests **Primary Outcome** Over half of all patients hospitalised with an ARD-ILD had a CURB-65≥2 (n=99, 55%) and NEWS-2 \geq 5 (n=114, 64%) on admission. Patients with ARD-IPF had a statistically higher baseline CURB-65 compared to those with non-IPF ARD-ILD diagnoses (median CURB-65 2 [IQR 1-4] versus 1 [IQR 1-3], P=0.0096), but baseline NEWS-2 scores were comparable (median NEWS-2 6 [IQR 3-8] versus 5 [IQR 2-8] respectively, P > 0.05) (Table 1). GAP score was found to have diminishing utility for in-hospital (AUC=0.604, P=0.087) and some merit at 30-days (AUC=0.642, P=0.015). CURB-65 showed modest predictive value for in-hospital (AUC=0.715, P<0.0001) and 90-day mortality (AUC=0.672, P<0.0001), with the optimal derived cut-off CURB-65\ge 2.5 in our previous study had high specificity (75, 88% respectively) but low sensitivity (57, 46% respectively) (Table 2). The optimal derived cut-off for CURB-65 in this cohort was 3.5. The NEWS-2 showed higher predictive value for in-hospital (AUC=0.803, P<0.0001) and 90-day mortality (AUC=0.751, P<0.0001). The optimal cut-off for NEWS-2≥6.5 was found to have high sensitivity (73%) and specificity (72%) for predicting 90-day mortality, in contrast to high sensitivity (83%) and moderate specificity (63%) for predicting in-hospital mortality (Table 2).

As the CURB-65 score correlated moderately to NEWS-2 score (R=0.552, *P*<0.0001), the combined ability of these two scores to predict mortality was assessed (Table 2). NEWS-2 retained significance to predict 90-day and in-hospital mortality after allowing for the effect of CURB-65 score (OR 1.34, *P*<0.0001, and OR 1.47, *P*<0.0001, respectively); however, CURB-65 was no longer a significant predictor after controlling for NEWS-2 for 90-day (OR 1.34, *P*=0.1648) or in-hospital mortality (OR 1.423, *P*=0.1791) (Supplementary Data 3). The addition of the GAP score improved the ability of the CURB-65 score to predict mortality (Table 2), with both GAP and CURB-65 retaining significance in each other's presence. In contrast, the GAP score only improved the ability of the NEWS-2 score to predict 30-day mortality.

Secondary Outcomes

The median length of stay for patients admitted with an ARD-ILD was 6 days, but variability was observed across the cohort (IQR 3-11 days). Small numbers of patients received advanced respiratory support during their admission (n=29, 16%) although supplementary oxygen was frequently prescribed (n=159, 89%) (Table 1). ARD-ILD associated mortality was high; 20% of hospitalisations resulted in death, with 30- and 90-day mortality following admission of 24% and 38% (n=68) respectively (Table 1). Survival curve analysis indicated that patients admitted with ARD-IPF had higher in-hospital and 90-day mortality than patients with non-IPF-ARD (Figure 2). Univariate Cox regression analysis indicated that increasing NEWS-2 score was associated with higher mortality risk in-hospital and at 90-days; however, increased admission CURB-65 scores were not associated with an increased mortality risk (Table 3). Neither were higher admission CURB-65 nor NEWS-2 scores found to be associated with increased hazard of in-hospital mortality.

Table 2: Outcomes of ROC curve analysis for evaluating optimal cut-off values for CURB-65, NEWS-2 and GAP scores, correlating with ARD-ILD mortality

Evaluation of the receiver operator curve (ROC) curve analysis for CURB-65, NEWS-2 and

GAP scores correlate with 30- and 90-day mortality, in addition to in-hospital mortality.

289

290

291

294

297298

| | AUC | 95% CI | P-value | Decision Point | Sensitivity | Specificity | Youden's Index (J) |
|-----------------------|---------|-------------|----------|-------------------|-------------|-------------|-----------------------|
| SINGLE DISEASE S | SEVERI | TY SCORES | | | • | | |
| CURB-65 | | | | | | | |
| In-hospital mortality | 0.715 | 0.620-0.810 | < 0.0001 | 3.5 | 0.200 | 0.965 | 0.17 |
| | | | | 2.5 | 0.571 | 0.746 | 0.32 |
| 30-day mortality | 0.650 | 0.553-0.746 | 0.0021 | 1.5 | 0.476 | 0.737 | 0.21 |
| 90-day mortality | 0.672 | 0.591-0.753 | < 0.0001 | 3.5 | 0.130 | 0.973 | 0.10 |
| | | | | 2.5 | 0.464 | 0.882 | 0.25 |
| NEWS-2 | | | | | | | |
| In-hospital mortality | 0.803 | 0.731-0.875 | < 0.0001 | 6.5 | 0.829 | 0.634 | 0.46 |
| 30-day mortality | 0.750 | 0.669-0.831 | < 0.0001 | 6.5 | 0.762 | 0.642 | 0.40 |
| 90-day mortality | 0.751 | 0.680-0.822 | < 0.0001 | 6.5 | 0.725 | 0.718 | 0.44 |
| GAP | | | | | | | |
| In-hospital mortality | 0.604 | 0.491-0.717 | 0.0869 | 4.5 | 0.607 | 0.554 | 0.16 |
| 30-day mortality | 0.642 | 0.541-0.744 | 0.0151 | 3.5 | 0.871 | 0.353 | 0.22 |
| 90-day mortality | 0.564 | 0.471-0.658 | 0.1887 | 4.5 | 0.545 | 0.568 | 0.11 |
| COMBINATION DI | SEASE S | SEVERITY SO | CORES | | | | |
| CURB-65 and NEW | S-2 | | | | | | |
| In-hospital mortality | 0.805 | 0.731-0.879 | < 0.0001 | 0.157 | 0.857 | 0.620 | 0.48 |
| 30-day mortality | 0.681 | 0.589-0.822 | < 0.0001 | 0.225 | 0.624 | 0.681 | 0.40 |
| 90-day mortality | 0.757 | 0.687-0.827 | < 0.0001 | 0.392 | 0.710 | 0.682 | 0.39 |
| CURB-65 and GAP | | | | | | | |
| In-hospital mortality | 0.764 | 0.671-0.856 | < 0.0001 | 0.207 | 0.679 | 0.739 | 0.41 |
| 30-day mortality | 0.761 | 0.677-0.846 | < 0.0001 | 0.140 | 0.903 | 0.504 | 0.41 |
| 90-day mortality | 0.727 | 0.646-0.809 | < 0.0001 | 0.335 | 0.673 | 0.663 | 0.34 |
| NEWS-2 and GAP | | | | | | | |
| In-hospital mortality | 0.802 | 0.745-0.895 | < 0.0001 | 0.239 | 0.679 | 0.802 | 0.48 |
| 30-day mortality | 0.810 | 0.732-0.888 | < 0.0001 | 0.177 | 0.839 | 0.639 | 0.48 |
| 90-day mortality | 0.752 | 0.675-0.828 | < 0.0001 | 0.342 | 0.782 | 0.642 | 0.43 |

AUC, area under curve; CI, confidence interval; GAP, Gender, Age, Physiology Score; ROC,

receiver operator characteristics. ROCs are provided within Supplementary Data 2 and 3.

Table 3: Association of baseline patient factors with in-hospital mortality and 90-day mortality following hospitalisation with ARD-ILD

Cox proportional hazard regression univariate analysis

| Analysis | Factor | Wald | HR | <i>P</i> -value | 95% CI |
|--------------------------|----------------|-------|-------|-----------------|-------------|
| In hospital mortality | GAP score | 0.365 | 1.089 | 0.5452 | 0.826-1.435 |
| | Smoking Status | 3.102 | 2.022 | 0.0778 | 0.924-4.428 |
| | CURB-65 score | 3.163 | 1.565 | 0.0747 | 0.955-2.562 |
| | NEWS-2 score | 3.841 | 1.188 | 0.0501 | 1.000-1.411 |
| | GAP score | 1.020 | 0.773 | 0.3132 | 0.469-1.274 |
| 90-day | Smoking Status | 2.016 | 1.676 | 0.1558 | 0.822-3.419 |
| mortality | CURB-65 score | 1.089 | 0.753 | 0.2967 | 0.442-1.283 |
| | NEWS-2 score | 4.251 | 1.231 | 0.0391 | 1.010-1.501 |

CI, confidence interval; GAP, Gender, Age, Physiology Score; HR, hazard ratio.

DISCUSSION

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

The identification of patients with poor prognosis among those with ARD-ILD remains a significant challenge and there are limited data addressing the utility of illness severity scores to predict outcomes of these patients. This prospective study suggests that, as a predictor of mortality in this patient cohort, the NEWS-2 score has good discriminatory value for predicting in-hospital mortality and moderate discriminatory value for predicting 90-day mortality in patients with ARD-ILD. To our knowledge, this is the first prospective evidence for utilising NEWS-2 as a tool to predict in-hospital and post hospitalisation morbidity. A previous retrospective cohort study conducted at one of the study hospitals found that both NEWS-2 and CURB-65 risk stratification tools were independent predictors of mortality in patients with IPF.⁴ The current study therefore confirms the findings of this previous retrospective cohort⁴ and hence NEWS-2 may represent a simple tool to help prognostication. Notably, the optimal derived cut-off value for NEWS-2 in predicting mortality across inpatient, 30- and 90-days was NEWS-2 ≥6.5, the same in both this prospective patient cohort and our previously reported retrospective cohort.⁴ The CURB-65 score was found to have little additional benefit for predicting mortality, either as an individual predictor or when used in exploratory analyses with NEWS-2. Furthermore, we found that CURB-65 was able to predict both 90-day and in-hospital mortality in ARD-ILD with high specificity but low sensitivity, in keeping with previous data from our IPF cohort⁴. Aligning with these findings, Yamazaki et al found that CURB-65, Pneumonia Severity Index (PSI) and Sequential Organ Failure Assessment (qSOFA) were all predictive of inpatient mortality from pneumonia in a retrospective study of 79 patients with IPF.²² In that study, the optimal CURB-65 cut-off value was ≥3.0, differing slightly from the value derived in our previous retrospective IPF cohort, but contrasting with the optimal cut-off

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

≥2.5 derived in this current prospective ILD cohort. Notably, the CURB-65 score did not add value to the ability of the NEWS-2 score to predict poor outcomes. In contrast, exploratory analyses indicate there is some evidence of increased predictive ability on outcomes when NEWS-2 and GAP scores are used in tandem. Overall, these findings from different centres and patient populations suggest that the disease severity scores show promise in predicting poor outcome following hospitalisation with acute respiratory deterioration. As reported before the emergence of SARS-CoV-2, patients hospitalised with ARD-IPF had a poor prognosis.^{4,23–25} The median survival in this cohort was 23 days, slightly shorter than the survival times in the literature ranging between 1 and 4 months after AE-IPF. ^{26–29} Whilst in-hospital and 90-day mortality rates were significantly higher in the IPF group than the non-IPF group, all admissions related to an ARD were associated with significant mortality; 24% and 38% for 30- and 90-day mortality, respectively. Our in-hospital mortality data supports early and frank discussions between patients/families and clinicians surrounding the high mortality associated with ARD, even in the context of potentially 'treatable' causes e.g. infection and pulmonary embolism. Furthermore, the high short-term mortality after discharge may prompt clinicians to consider early discussions surrounding palliation and/or transplantation in suitable candidates. There were few admissions secondary to AE-ILD, which prevented further detailed analyses of any differences in the mortality between AE-ILD and other parenchymal causes of ARD. Teramachi et al showed 90-day mortality of AE-IPF patients was significantly higher than ARD due to other parenchymal causes (46% (16/35) vs 17% (12/71) respectively; P=0.002). It is not possible to ascertain fully to what extent healthcare access and patient behaviour during the pandemic affected these outcomes. The Task Force for Lung Health

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

suggested that over a third of people with pre-existing lung problems felt pressure to avoid or delay seeking treatment.³⁰ Hence, patients may have delayed presentation to hospital. Alternatively, the emergence of a novel pathogen may have affected outcomes of patients with ARD, either directly or indirectly through changes in the epidemiology of other acute respiratory infection, treatment pathways or other aspects of patient healthcare provision. In non-ILD patients hospitalised with SARS-CoV-2 infection, NEWS-2 correlates moderately well with severe outcomes such as ITU admission, positive airway pressure support or death; however, there were no such significant correlations for CURB-65 (P>0.05).³¹ This study has many strengths. It was undertaken as a prospective two site cohort study which screened hospital admissions for signs/symptoms of acute respiratory disease. This study therefore does not rely on ICD-10 coding or solely on data-linkage. There were minimal missing data, and the study includes adults who lack capacity to consent through a consultee and by specific authorisation to use certain data without consent, thereby ensuring full ascertainment of ARD-ILD during this period. The medical records were linked with community records to obtain detailed and accurate data for each study participant. There are also some limitations of this study. First, we assessed ARD-ILD at both acute care NHS hospitals in Bristol and 83% of this cohort is Caucasian; therefore, we cannot be sure that results are generalisable to other patient populations. Second, we used vital statistics to determine mortality, and did not ascertain the specific cause of death. Third, the number of acute exacerbations in this cohort was low, we were therefore unable to confirm our previous findings that mortality associated with ARD-ILD was high, irrespective of the underlying cause for the deterioration. Lastly, it is difficult to determine whether healthcare access may have affected time to hospitalisation and hence outcomes, as previously mentioned.

CONCLUSION

Simple illness severity scores may permit refinement of ARD management of ILD patients and if survival to discharge is achieved, permit early discussion with patients, referral to transplantation or palliative care planning as appropriate.

REFERENCES

387

- 1. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute
- Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
- 390 Am J Respir Crit Care Med. 2016 Aug 1;194(3):265–75.
- 391 2. Cottin V, Schmidt A, Catella L, Porte F, Fernandez-Montoya C, Le Lay K, et al. Burden
- of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study.
- 393 PLoS One. 2017;12(1):e0166462.
- 394 3. Moua T, Westerly BD, Dulohery MM, Daniels CE, Ryu JH, Lim KG. Patients With
- Fibrotic Interstitial Lung Disease Hospitalized for Acute Respiratory Worsening: A Large
- 396 Cohort Analysis. Chest. 2016 May;149(5):1205–14.
- 4. Hyams C, Hettle D, Bibby A, Adamali HA, Barratt SL. Utility of illness severity scores
- 398 to predict mortality in patients hospitalised with respiratory deterioration of Idiopathic
- 399 Pulmonary Fibrosis. QJM. 2020 Jul 1;hcaa214.
- 400 5. Kolb M, Bondue B, Pesci A, Miyazaki Y, Song JW, Bhatt NY, et al. Acute exacerbations
- of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018 Dec
- 402 31;27(150):180071.
- 403 6. Southern BD. Patients with interstitial lung disease and pulmonary sarcoidosis are at high
- risk for severe illness related to COVID-19. Cleve Clin J Med. 2020 Jun 18;
- 405 7. Esposito AJ, Menon AA, Ghosh AJ, Putman RK, Fredenburgh LE, El-Chemaly SY, et al.
- Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A
- 407 Case-Control Study. Am J Respir Crit Care Med. 2020 Dec 15;202(12):1710–3.
- 408 8. Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H, Agnew S, et al. Outcome
- of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An
- 410 International Multicenter Study. Am J Respir Crit Care Med. 2020 Dec 15;202(12):1656–
- 411 65.
- 412 9. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al.
- 413 Defining community acquired pneumonia severity on presentation to hospital: an
- international derivation and validation study. Thorax. 2003 May;58(5):377–82.
- 415 10. Chang CL, Sullivan GD, Karalus NC, Mills GD, McLachlan JD, Hancox RJ. Predicting
- early mortality in acute exacerbation of chronic obstructive pulmonary disease using the
- 417 CURB65 score. Respirology. 2011 Jan;16(1):146–51.
- 418 11. Smith MEB, Chiovaro JC, O'Neil M, Kansagara D, Quiñones AR, Freeman M, et al.
- 419 Early warning system scores for clinical deterioration in hospitalized patients: a
- 420 systematic review. Ann Am Thorac Soc. 2014 Nov;11(9):1454–65.
- 421 12. Smith GB, Prytherch DR, Meredith P, Schmidt PE. Early warning scores: unravelling
- detection and escalation. Int J Health Care Qual Assur. 2015;28(8):872–5.
- 423 13. Kim I, Song H, Kim H, Park K, Kim SH, Oh S, et al. Use of the National Early Warning
- 424 Score for predicting in-hospital mortality in older adults admitted to the emergency
- department. Clinical and Experimental Emergency Medicine. 2020 Mar 31;7:61–6.

- 426 14. Teramachi R, Kondoh Y, Kataoka K, Taniguchi H, Matsuda T, Kimura T, et al.
- Outcomes with newly proposed classification of acute respiratory deterioration in
- idiopathic pulmonary fibrosis. Respir Med. 2018 Oct;143:147–52.
- 429 15. ISRCTN ISRCTN17354061: A pan-pandemic respiratory infection surveillance study
- [Internet]. [cited 2021 Oct 6]. Available from: https://www.isrctn.com/ISRCTN17354061
- 431 16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
- data capture (REDCap)--a metadata-driven methodology and workflow process for
- providing translational research informatics support. J Biomed Inform. 2009
- 434 Apr;42(2):377–81.
- 435 17. Kolb M, Collard HR. Staging of idiopathic pulmonary fibrosis: past, present and future.
- 436 Eur Respir Rev. 2014 Jun;23(132):220–4.
- 437 18. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A
- multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern
- 439 Med. 2012 May 15;156(10):684–91.
- 19. Smith GB, Prytherch DR, Jarvis S, Kovacs C, Meredith P, Schmidt PE, et al. A
- Comparison of the Ability of the Physiologic Components of Medical Emergency Team
- Criteria and the U.K. National Early Warning Score to Discriminate Patients at Risk of a
- Range of Adverse Clinical Outcomes. Crit Care Med. 2016 Dec;44(12):2171–81.
- 20. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute
- Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
- 446 Am J Respir Crit Care Med. 2016 Aug 1;194(3):265–75.
- 447 21. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating
- characteristic (ROC) curve. Radiology. 1982 Apr 1;143(1):29–36.
- 449 22. Yamazaki R, Nishiyama O, Yoshikawa K, Saeki S, Sano H, Iwanaga T, et al.
- 450 Comparison of CURB-65, PSI, and qSOFA for predicting pneumonia mortality in
- patients with idiopathic pulmonary fibrosis. Sci Rep. 2021 Feb 16;11(1):3880.
- 452 23. Salonen J, Vähänikkilä H, Purokivi M, Kaarteenaho R. Causes of acute respiratory
- hospitalizations predict survival in fibrosing interstitial lung diseases. PLOS ONE. 2020
- 454 Nov 30;15(11):e0242860.
- 455 24. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, et al. Acute
- exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007 Oct
- 457 1;176(7):636–43.
- 458 25. Kondoh Y, Cottin V, Brown KK. Recent lessons learned in the management of acute
- exacerbation of idiopathic pulmonary fibrosis. European Respiratory Review [Internet].
- 460 2018 Jun 30 [cited 2022 Jul 6];27(148). Available from:
- https://err.ersjournals.com/content/27/148/175050
- 462 26. Arai T, Kagawa T, Sasaki Y, Sugawara R, Sugimoto C, Tachibana K, et al.
- 463 Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial
- pneumonia. Respirology. 2016 Nov;21(8):1431–7.

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482 483 27. Cao M, Sheng J, Qiu X, Wang D, Wang D, Wang Y, et al. Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a populationbased study. BMC Pulmonary Medicine. 2019 Nov 14;19(1):215. 28. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C, for the IPFnet investigators. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respiratory Research. 2013 Jul 13;14(1):73. 29. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. European Respiratory Journal. 2011 Feb 1;37(2):356-63. 30. Over a third of people with lung conditions felt pressure to avoid or delay seeking treatment during lockdown - British Lung Foundation [Internet]. Asthma + Lung UK. 2020 [cited 2022 Jul 6]. Available from: https://www.blf.org.uk/taskforce/pressrelease/over-a-third-of-people-with-lung-conditions-felt-pressure-to-avoid-or-delayseeking-treatment 31. Arnold DT, Attwood M, Barratt S, Morley A, Elvers KT, McKernon J, et al. Predicting outcomes of COVID-19 from admission biomarkers: a prospective UK cohort study. Emerg Med J. 2021 Jul;38(7):543–8.

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

FIGURE LEGENDS Figure 1. Adults hospitalised with acute respiratory deterioration of interstitial lung disease (A) Flow diagram of study participants and (B) aetiology of acute respiratory deterioration of Interstitial lung disease (ARD-ILD). ARD; acute respiratory deterioration; AE-ILD, acute exacerbation of interstitial lung disease; LRTI, lower respiratory tract infection; COVID-19, coronavirus disease 2019; HF, heart failure. +n=11 COVID-19 pneumonia, one aspiration pneumonia, one hospitalised pneumonia, remainder deemed to be community acquired pneumonia *including 3 with symptomatic COVID-19 but no CXR infiltrates ^ unclassified – CT not performed and CRP < 50. Figure 2: ARD-ILD survival curve analysis Kaplan Meier survival curves for (A) in-hospital and (B) 90-day mortality, for patients admitted with ARD-IPF (green line) and non-IPF ARD-ILD (blue line).

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

AUTHOR CONTRIBUTIONS CH, RW, PW, AF and SLB generated the research question and analysis plan. The data for this study was collected by the AvonCAP Research Team, CH, RW, JR, MGG and ZSB. CH, MGG, ZSB and RW verified the data. RW, CH, PW, AF and SLB undertook data analysis. All authors were involved in the final manuscript preparation and its revisions before publication. AF and SB provided oversight of the research. **ACKNOWLEDGEMENTS** The authors would like to acknowledge the Research Teams at North Bristol NHS and University Hospitals Bristol and Weston NHS Trusts, including Helen Lewis-White, Diana Benton, Anna Morley, Jade King and Nicola Manning. Furthermore, we would like to acknowledge the significant contribution to the AvonCAP study made by Rachel Davies, Adam Taylor, Mai Baquedano and the IT team, including Stuart Robinson, at North Bristol NHS Trust. **DATA SHARING** The data used in this study are sensitive and cannot be made publicly available without breaching patient confidentiality regulations. Therefore, individual participant data and a data dictionary are not available to other researchers. **DECLARATION OF INTEREST** CH is Principal Investigator of the AvonCAP study, which is an investigator-led University of Bristol study funded by Pfizer, Inc, and is currently a member of the BTS Pulmonary Infection Specialty Advisory Group (SAG). AF is a member of the Joint Committee on Vaccination and Immunization (JCVI) and chair of the World Health Organization European

Technical Advisory Group of Experts (WHO ETAGE) committee. In addition to receiving funding from Pfizer as Chief Investigator for this study, he leads another project investigating transmission of respiratory bacteria in families jointly funded by Pfizer and the Gates The other authors declare no competing interests.

The AvonCAP Research Group

529

| AUTHOR | AFFILIATION | | |
|------------------------|---|--|--|
| David Adegbite | Bristol Vaccine Centre, University of Bristol | | |
| Rupert Antico | Bristol Vaccine Centre, University of Bristol | | |
| Francesca Bayley | Bristol Vaccine Centre, University of Bristol | | |
| Beth Begier | Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, USA | | |
| Maddalena Bellavia | North Bristol NHS Trust | | |
| Emma Bridgeman | Bristol Vaccine Centre, University of Bristol | | |
| Julia Brzezinska | Clinical Research and Imaging Centre, UHBW NHS Trust | | |
| James Campling | Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, USA | | |
| Natalie Chang | Clinical Research and Imaging Centre, UHBW NHS Trust | | |
| Julie Cloake | Clinical Research and Imaging Centre, UHBW NHS Trust | | |
| Madeleine Clout | Bristol Vaccine Centre, University of Bristol | | |
| Pip Croxford | North Bristol NHS Trust | | |
| Gillian Ellsbury | Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, UK | | |
| Bradford Gessner | Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, USA | | |
| Niall Grace | Bristol Vaccine Centre, University of Bristol | | |
| Sharon Gray | Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, USA | | |
| Oliver Griffiths | Clinical Research and Imaging Centre, UHBW NHS Trust | | |
| Charli Grimes | North Bristol NHS Trust | | |
| Lucy Grimwood | Bristol Vaccine Centre, University of Bristol | | |
| Zsolt Friedrich | North Bristol NHS Trust | | |
| Leah Fleming | Bristol Vaccine Centre, University of Bristol | | |
| Kazminder Fox | Clinical Research and Imaging Centre, UHBW NHS Trust | | |
| Milo Jeenes-Flanagan | Bristol Vaccine Centre, University of Bristol | | |
| Luis Jodar | Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, USA | | |
| Johanna Kellett Wright | Clinical Research and Imaging Centre, UHBW NHS Trust | | |
| Jane Kinney | Bristol Vaccine Centre, University of Bristol | | |
| Robyn Heath | Clinical Research and Imaging Centre, UHBW NHS Trust | | |
| Kate Helliker | North Bristol NHS Trust | | |
| Robyn Huber | Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, USA | | |
| Amelia Langdon | Bristol Vaccine Centre, University of Bristol | | |
| Rajeka Lazarus | Clinical Research and Imaging Centre, UHBW NHS Trust | | |
| Sandi Nammuni | Clinical Research and Imaging Centre, UHBW NHS Trust | | |
| Arachchge | | | |
| Vicki Mackay | Clinical Research and Imaging Centre, UHBW NHS Trust | | |
| Robin Marlow | Bristol Vaccine Centre, University of Bristol | | |
| Zandile Maseko | North Bristol NHS Trust | | |

| Anya Mattocks | Bristol Vaccine Centre | |
|----------------------|--|--|
| Katie Maughan | Clinical Research and Imaging Centre, UHBW NHS Trust | |
| Nicola Manning | Clinical Research and Imaging Centre, UHBW NHS Trust | |
| Katarina Milutinovic | Clinical Research and Imaging Centre, UHBW NHS Trust | |
| Konstantina Minou | Clinical Research and Imaging Centre, UHBW NHS Trust | |
| Anna Morley | North Bristol NHS Trust | |
| Taslima Mona | Clinical Research and Imaging Centre, UHBW NHS Trust | |
| Claire Mitchell | Clinical Research and Imaging Centre, UHBW NHS Trust | |
| Leigh Morrison | North Bristol NHS Trust | |
| Bethany Osborne | Clinical Research and Imaging Centre, UHBW NHS Trust | |
| Fiona Perkins | Clinical Research and Imaging Centre, UHBW NHS Trust | |
| Tawassal Riaz | Clinical Research and Imaging Centre, UHBW NHS Trust | |
| Gabriella Ruffino | North Bristol NHS Trust | |
| Peter Sequenza | Bristol Vaccine Centre, University of Bristol | |
| Lily Smart | Bristol Vaccine Centre, University of Bristol | |
| Emma Scott | Clinical Research and Imaging Centre, UHBW NHS Trust | |
| Jo Southern | Vaccines Medical Development, Scientific & Clinical Affairs, Pfizer Inc, UK | |
| Seevakumar Suppiah | North Bristol NHS Trust | |
| Zoe Taylor | Bristol Vaccine Centre, University of Bristol | |
| Grace Tilzey | Clinical Research and Imaging Centre, UHBW NHS Trust | |
| Anabella Turner | Clinical Research and Imaging Centre, UHBW NHS Trust | |
| Gabriella Valentine | Bristol Vaccine Centre, University of Bristol | |
| Marianne Vasquez | North Bristol NHS Trust | |
| Rhian Walters | Clinical Research and Imaging Centre, UHBW NHS Trust | |
| Lana Ward | North Bristol NHS Trust | |
| Louise Wright | North Bristol NHS Trust | |







